Our pipeline shows the progress we and our partners are making on products in development for priority infectious diseases. For an explanation of development phases, visit our clinical development page.
HIV vaccine & antibody candidates
eOD-GT8 60mer mRNA + Core-g28v2 60mer mRNA
HIVPartners
Bill & Melinda Gates Foundation; Collaboration for AIDS Vaccine Discovery Vaccine Immunology Statistical Center; Duke University; Emory University; Fred Hutchinson Cancer Center; George Washington University; Moderna; Scripps Research; United States Institutes of Health Vaccine Research Center; University of Texas San Antonio
eOD-GT8 60mer mRNA
HIVPartners
Aurum Institute (Tembisa, South Africa); Bill & Melinda Gates Foundation; Center for Family Health Research (Kigali, Rwanda); Moderna; Scripps Research; United States Agency for International Development
rVSVΔG-Env-HIV
HIVPartners
Government of Japan
Triple antibody combination product
HIVPartners
Scripps Research; United States Agency for International Development; United States National Institutes of Health and its clinical trial networks; University of Oslo
Emerging infectious diseases vaccine candidates
rVSVΔG-LASV-GPC
Lassa FeverPartners
Batavia Biosciences; Brigham and Women’s Hospital (Phase 1); Charles River Laboratories; Coalition for Epidemic Preparedness; East West Medical Research Institute Liberia (Phase 1); EpiCentre; European & Developing Countries Clinical Trials Partnership; George Washington University (Phase 1); Imperial College London; IQVIA; La Jolla Institute for Immunology; Kenema Government Hospital; Merck Advisory Group; NeoGenomics Laboratories; Noguchi Memorial Institute for Medical Research, Ghana (Phase 2a); PREVAIL JFK Hospital Liberia (Phase 2a); PREVAIL Redemption Hospital (Phase 1); Public Health Agency of Canada; Seattle Children’s Research Institute; The George Washington University; Tulane University; Walter Reed Program, Nigeria (Phase 2a)
rVSV∆G-SUDV-GP
Ebola Sudan VirusPartners
Batavia Biosciences; Biomedical Advanced Research and Development Authority (BARDA); BioReliance; Boston University’s National Emerging Infectious Diseases Laboratories; Charles River Laboratories; Imperial College London; IQVIA; La Jolla Institute for Immunology; Merck Advisory Group; NeoGenomics Laboratories; Public Health Agency of Canada; Seattle Children’s Research Institute; Tulane University; University of Texas Medical Branch at Galveston; Viral Hemorrhagic Fever Consortium
rVSV∆G-MARV-GP
Marburg VirusPartners
Batavia Biosciences; Charles River Laboratories; Defense Threat Reduction Agency; Imperial College London; IQVIA; La Jolla Institute for Immunology; Merck Advisory Group; Public Health Agency of Canada; Seattle Children’s Research Institute; Texas Biomedical Research Institute; University of Texas Medical Branch at Galveston; Viral Hemorrhagic Fever Consortium
rVSV∆G-SARS-CoV-2
COVID-19Partners
Batavia Biosciences; Boston University’s National Emerging Infectious Diseases Laboratory; Charles River Laboratories; Defense Threat Reduction Agency; Government of Japan; Imperial College London; Merck Advisory Group; Neogenomics Laboratories; PATH; Public Health Agency of Canada; University of North Carolina at Chapel Hill
Tuberculosis (TB) vaccine candidates
MTBVAC
TuberculosisPartners
Bill & Melinda Gates Foundation; Biofabri S.L.; Open Philanthropy; Universidad de Zaragoza
MTBVAC (People living with HIV)
TuberculosisPartners
Biofabri S.L., HIV Vaccine Trials Network; National Institute of Allergy and Infectious Diseases; South African Tuberculosis Vaccine Initiative; Universidad de Zaragoza
mRNA-encoded TB antigens
TuberculosisPartners
Moderna; Trudeau Institute; U.S. National Institute of Allergy and Infectious Diseases; U.S. National Institutes of Health; University of Georgia